



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Ms W van Bentum-Puijk
UNIVERSITY MEDICAL CENTRE UTRECHT
CELL THERAPY FACILITY, HEIDELBERGLAAN 100, UTRECHT, NL-3584 CX, NETHERLANDS

16/06/2021

Dear Ms W van Bentum-Puijk,

NOTICE OF NON-ACCEPTANCE OF AMENDMENT

Our Reference:	CTA 30913/0006/001-0018
Eudract Number:	2015-002340-14
Product:	ceftriaxone, levofloxacin, piperacilin-tazobactam, hydrocortisone, amoxicillin-clavulanate, azithromycin, clarithromycin, moxifloxacin, ceftaroline, hydroxychloroquine, Tocilizumab, Sarilumab, Heparin, Sarilumab unlicensed, Kaletra 80mg/20mg Oral Solution, interferon beta-1a, anakinra, Lopinavir/Ritonavir Mylan, Ascorbic Acid, simvastatin, Ramipril, Lisinopril, Perindopril, Enalapril, Captopril, losartan, Valsartan, Candesartan, Irbesartan, Repagermanium
Protocol number:	n/a
Substantial Amendment Code Number:	AM026

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 1031

I refer to your notice of amendment received on 03/06/2021 concerning a proposed amendment to the terms of your request for a Clinical Trial Authorisation or to the particulars or documents that accompanied it. The Licensing Authority has carefully considered the proposed amendment but has decided, in accordance with regulation 24(5) of the Regulations, not to accept it on the following grounds.

Grounds for Non-Acceptance:

MEDICAL - Remarks: The DMX-200 IB is not approvable as it does not contain a reference safety information section.

For guidance on RSI please refer to the link provided;

http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2017_11_CTFG_Question_and_Answer_on_Reference_Safety_Information_2017.pdf



The CTU COVID assessment team offer a pre-assessment service if the Sponsor would like a review of the modified IB prior to re-submitting a substantial amendment. The resubmitted substantial amendment will receive an expedited review.

For further information email; lisa.campbell@mhra.gov.uk

If you believe it is possible to modify or adapt the proposed amendment to the protocol in order to address the concerns set out in the grounds for non-acceptance, you may respond, up to at least 14 days before the amendment is to be made, by giving written notice to the Authority and the relevant ethics committee in accordance with regulation 25(2). Any other modifications to the original notice of amendment that are required to address the grounds for non-acceptance will need to be submitted as a new valid notice of amendment.

Yours sincerely,

Clinical Trials Unit
MHRA